Background Celiac disease (CD), an autoimmune enteropathy triggered by the intake of gluten,
is a widespread pathology, with a worldwide estimated prevalence of approximately 1%,
characterized by both gastrointestinal and systemic symptoms, both in adults and children,
which are usually resolved by eliminating gluten from the diet (Gluten-Free Diet, GFD).
However, it still remains an under-diagnosed condition (to date the overall prevalence in
Italy is 0.37% and in Sicily 0.35%).
Although, CD is often associated with malabsorption symptoms (steatorrhea, weight loss,
nutritional deficits, etc.), a growing number of affected subjects are overweight or frankly
obese. One of the conditions that is most frequently detected in pauci/asymptomatic subjects
is an increase in transaminases, which often regresses completely after the start of GFD.
More recently, a specific liver disorder has shown a certain relevance in patients suffering
from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has
cited it among the possible comorbidities which should be screened in CD subjects:
Non-Alcoholic Fatty Liver Disease (NAFLD). This condition affects approximately 34% of
overweight or frankly obese children and is closely related, both in children and adults, to
the traits of metabolic syndrome, so much so that today it is preferably referred to as
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In adults, a non-random
association between CD and NAFLD has been demonstrated, showing a CD prevalence of 2-14%
among patients with NAFLD. Few studies have focused on this same aspect in pediatric age,
however reporting that the prevalence of CD among children with NAFLD could be comparable to
the prevalence of CD in the general pediatric population. Nevertheless, a study conducted on
11488 children (0-19 years) affected by CD compared with 57029 healthy children supports the
hypothesis of a close association between CD and NAFLD in childhood. Authors proved a 4.6
relative risk value of NAFLD in CD patients.
Several factors have been advocated as putative responsible for this association: 1) dietary
imbalances due to the adoption of GFD, rich in fats and sugars and low in fiber; 2)
alteration of intestinal permeability, with an increase in the translocation of bacterial
substances from the gut, which, are transported directly to the liver, where they are able to
generate inflammatory processes mediated by the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB), activated by the Tool-like receptor 4 (TLR4)-Lipopolysaccharide
(LPS)-LPS Binding Protein (LPB) complex, with production of proinflammatory cytokines [Tumor
Necrosis Factor (TNF)-α, Interleukine (IL)-1β, IL-6, IL-12, IL-18); 3) alterations of the
intestinal microbiota.
Objectives. Primary objective: define, retrospectively, the prevalence of NAFLD in a pediatric population
affected by CD and study its possible association with GFD:
Objective 1.1: identify the prevalence of NAFLD before the introduction of the GFD in an
already diagnosed pediatric celiac; Objective 1.2: identify the prevalence of NAFLD after at
least 12 months of GFD in an already diagnosed pediatric celiac; Objective 1.3: compare the
prevalence of NAFLD before and after (at least 12 months) the introduction of the GFD in all
pediatric celiac patients for whom both pre- and post-GFD data are available; Objective 1.4:
establish a possible correlation between the presence/absence of NAFLD, both before and after
the adoption of the GFD, and clinical, laboratory, immunological, genetic and histological
parameters, in order to identify a subgroup of celiac children potentially predisposed to the
NAFLD development; Objective 1.5: establish any changes in the clinical, laboratory,
immunological, genetic and histological parameters of the population referred to in objective
1.3 and establish whether there is a correlation between these and the possible
onset/regression of NAFLD.
Secondary objective: define the possible role of the intestinal permeability alteration
and/or the intestinal mucosa damage and/or the proinflammatory status in the development of
NAFLD in children affected by CD:
Objective 2.1: identify the possible presence of serological markers of altered intestinal
permeability and/or intestinal mucosa damage in a population of celiac children prospectively
enrolled at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" before the start
of the GFD (T0).
Objective 2.2: Identify the possible presence of blood markers of inflammation in the
population referred to in point 2.1 at T0.
Objective 2.3: define the existence of an association between the markers of altered
intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD
in the population referred to in point 2.1 at T0.
Objective 2.4: evaluate any changes in serological markers of altered intestinal permeability
and/or mucosal damage in the population referred to in point 2.1 after 6 months of strict
adherence to the GFD (T1).
Objective 2.5: evaluate any changes in blood markers of inflammation in the population
referred to in point 2.1 at T1.
Objective 2.6: define the existence of an association between the markers of altered
intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD
in the population referred to in point 2.1 at T1.
Materials and methods Primary objective To achieve the primary objective of the study, all
the medical records of pediatric patients suffering from CD already diagnosed according to
the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)
criteria at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" will be
retrospectively analyzed.
Objectives 1.1, 1.2 and 1.3 To achieve objectives 1.1 and 1.2, the presence and degree of
steatosis diagnosed by abdominal ultrasound will be assessed before the start of the GFD
(objective 1.1) or after at least 12 months from the introduction of the GFD (objective 1.2).
To achieve objective 1.3, a sub-analysis of the presence and degree of steatosis will be
performed in all those patients who have undergone an abdominal ultrasound both before and
after the introduction of GFD.
Objectives 1.4 and 1.5 To achieve objective 1.4, clinical (sex, ethnicity, age at diagnosis,
BMI, symptoms, duration of GFD), laboratory (transaminasemia, albuminemia, total
cholesterolemia and subclasses, triglyceridemia, fasting glycemia, insulinemia, Homeostasis
Model Assessment-Insulin Resistance HOMA-IR Index), immunological [anti-gliadin antibodies
(AGA), anti-tissue transglutaminase antibodies (tTG), anti-endomysial antibodies (EMA)],
genetic (HLA structure) and histological (Marsh duodenal histological classification,
presence of eosinophilic infiltration, etc.) data of all included patients will be collect,
both before (target population 1.1) and after (target population 1.2) the introduction of the
GFD.
To achieve objective 1.5, the same clinical, laboratory, immunological, genetic and
histological parameters analyzed for objective 1.4 will be analyzed, if available both before
and after the introduction of the GFD, in order to establish whether there is a correlation
between these and the possible onset/regression of NAFLD in the population referred to in
objective 1.3.
Secondary objective To achieve the secondary objective of the study, pediatric patients
affected by newly diagnosed CD according to the ESPGHAN criteria will be prospectively
enrolled at the at the Pediatric Clinic of the Children's Hospital "G. Di Cristina". The
number of subjects to be enrolled will be equal to 91, considering, in the Province of
Palermo, Sicily, Italy, a pediatric population (between 0 and 14 years) of 170,468 subjects,
a prevalence of CD equal to 1%, a confidence level of 95% and a confidence interval of 10%.
Furthermore, as the exact prevalence of NAFLD in children with CD it's not clearly defined,
results derived from the retrospective part of this study (objective 1.1) will be used to
maintain a proportion between subjects enrolled without and with pre-GFD NAFLD ("competitive
enrollment").
Objectives 2.1, 2.2, 2.3 To achieve objective 2.1, all enrolled subjects, for whom the same
clinical, laboratory, immunological, genetic and histological parameters analyzed for
objective 1.4 must be available (the latter only if necessary for diagnosis), in order to
make a comparison possible, will be subjected to blood sampling for the identification of
serological markers of altered intestinal permeability [zonulin (Zo), occludin (OCLN),
anti-OCLN antibodies, claudin 1 (CLDN1) and anti-CLDN1 antibodies] and mucosal damage
[Intestinal Fatty Acid Binding Protein 2 (iFABP2)], lipopolysaccharide (LPS),
lipopolysaccharide binding protein (LPB)] before starting the GFD (T0). The blood sampling
will coincide with the one necessary for the diagnostic definition of the patient's clinical
picture.
To achieve objective 2.2, all enrolled subjects will undergo a blood sample before starting
the GFD (T0), for the identification of the following inflammatory markers: TNF-α, IL-1β,
IL-6, IL-12, IL-18. The blood sampling will coincide with the one necessary for the
diagnostic definition of the patient's clinical picture.
To achieve objective 2.3, all enrolled subjects, before starting the GFD (T0), will undergo
an abdominal ultrasound to study hepatic steatosis according to the methods previously
described and a statistical correlation analysis will be carried out between the
presence/absence of NAFLD and the markers assayed for objective 2.1 and 2.2.
The assay of intestinal permeability and mucosal damage markers will be carried out using the
ELISA method, with commercially available kits, following the manufacturers' instructions.
The measurement of inflammation markers will be performed by intracellular staining with flow
cytometric method on peripheral blood mononuclear cells (PBMC) extracted from patients' blood
samples.
Objectives 2.4, 2.5, 2.6 To achieve objective 2.4, all enrolled subjects, for whom the same
clinical, laboratory and immunological parameters analyzed at T0 must be available, in order
to make a comparison possible, will be subjected to a blood sample for the identification of
serological markers of altered intestinal permeability and mucosal damage already measured at
T0 (see objective 2.1), after 6 months of strict adherence to the GFD (T1). The blood
sampling will coincide with the one necessary to re-evaluate the patient's clinical picture
after 6 months of adherence to the GFD.
To achieve objective 2.5, all enrolled subjects will undergo a blood sample to identify the
inflammation markers already dosed at T0 (see objective 2.2), after 6 months of strict
adherence to the GFD (T1). The blood sampling will coincide with the one necessary to
re-evaluate the patient's clinical picture after 6 months of adherence to the GFD.
To achieve objective 2.6, all enrolled subjects, after 6 months of strict adherence to the
GFD (T1), will undergo abdominal ultrasound to study hepatic steatosis according to the
methods previously described and a statistical correlation analysis will be carried out
between the presence/absence of NAFLD and the markers assayed for objective 2.4 and 2.5.
The assessment of adherence to the GFD will be carried out through the monthly compilation,
by the children and/or their parents, of a specifically created and validated questionnaire.
